Novonix Limited (NVX) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.
Les analystes estiment Bénéfice par action (EPS) de $-0.40 et chiffre d'affaires de $0.01B pour le prochain exercice fiscal.
Historique du Bénéfice par action (EPS): 2024: réel $-0.60 vs est $-0.40 (manqué -50.5%). 2025: réel $-0.52 vs est $-0.35 (manqué -48.6%). Précision des analystes: 67%.
Estimations du BPA — NVX
67%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$0.60
vs Est –$0.40
▼ 33.6% off
2025
Actual –$0.52
vs Est –$0.35
▼ 32.7% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Estimations du CA — NVX
76%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.006B
vs Est $0.008B
▼ 42.0% off
2025
Actual $0.006B
vs Est $0.006B
▼ 5.7% off
Revenue Trend
Revenue has been relatively flat. Analysts forecast significant revenue growth ahead.
Les autres consultent aussi
